Charting, page-1332

I am surprised that 14c has so far proven to be such a strong support even without any significant updates. That's a great news! IBX is all or nothing opportunity, as biopharma and biotech often tend to be. The science is there and the theory is sound, so if IBX does pull through, this could potentially be an _all_ opportunity, a once in a lifetime share to hold. A JV with a giant like Siemens, while IBX keeps expanding its pipeline from breast cancer to other types of cancer -- not a one trick pony, but a company with a potential to grow bigger, from market cap of $100M to $500M, from $500M to $1B, etc. I am not even going to get into all the other potential applications of nanoparticles. This is an industry that has barely been discovered by the mainstream.